Cambridge, UK, 6th October 2022 / Amphista Therapeutics Ltd., a global leader in the discovery and development of next generation targeted protein degradation (TPD) therapeutics and recently named Fierce Biotech, Fierce 15 winner for 2022, has selected Domainex Ltd as one of its trusted partners to provide integrated drug discovery services to support its research programmes. Domainex, a leading, multi-award winning, integrated medicines research services partner, will provide expertise in protein production, assay biology and medicinal chemistry.
Domainex has experience in the field of TPD with expertise in designing, synthesising, and profiling targeted heterobifunctional protein degraders. Domainex has established in vitro binary and ternary complex formation assays to confirm target engagement using its suite of biophysical technologies. This expertise makes Domainex an ideal partner to support Amphista’s TPD programmes.
“We are delighted to have been selected by Amphista Therapeutics to help them advance their portfolio of drug discovery projects, building on our previous collaboration,” said Tom Mander, CEO of Domainex. “Our skilled, multi-disciplinary, integrated team of medicinal chemists, cell biologists, biophysicists and protein scientists based at our Centres of Excellence within the Cambridge bioscience hub will work closely with the scientific leadership team at Amphista to advance their cutting-edge protein degrading technology. This new contract is further testament to the appeal of the innovative and unique drug discovery platform we have created to enrich the medicines pipeline of our partners.”
Amphista CEO, Nicki Thompson, added, “Amphista is expanding rapidly at our Granta Park, Cambridge, UK research hub as we advance our growing internal TPD portfolio and our recently signed research collaborations with BMS and Merck Healthcare. To support our planned growth, we’re also excited to expand our network of contract research collaborators and work with Domainex with their high-quality chemistry, assay biology & biophysical expertise as we tap into the rich expertise in the Cambridge, UK area.”
ENDS
For more information, contact:
Domainex
Dr Tom Mander, CEO
E: tom.mander@domainex.co.uk
Sciad Communications
Deborah Cockerill / Juliette Craggs / Jasmin Shearan
T: +44 (0)20 3405 7892
E: domainex@sciad.com
Amphista Therapeutics
Lynn Granito
Berry & Company Public Relations
E: lgranito@berrypr.com
T: +1 212 253 8881
Notes to editors
About Domainex Ltd.
Domainex is a leading, multi-award-winning, integrated medicines research service partner working with ambitious life science organizations from around the globe. The Company has been setting new standards in research since 2001, working collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions globally.
Domainex provides innovative and customized wet and dry biology and chemistry services to advance the disease research projects of its partners, from target expression to pre-clinical development candidate nomination. Working with Domainex maximizes the chance of successful progression for its partners’ research. Domainex’s innovative science and extensive technical capabilities enable it to create novel candidate medicines to treat debilitating diseases. Domainex works closely and collaboratively with its partners to understand their aspirations, bringing ideas, know-how and a wealth of experience to bear on their projects.
Domainex’s highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges, including being named on over 60 patent applications of numerous candidate drugs. The Company aims to deliver successful outcomes efficiently and quickly, setting the highest possible benchmark in medicines research.
Full information about Domainex and its award-winning services can be found at www.domainex.co.uk.
About Amphista Therapeutics Ltd.
Amphista Therapeutics is a global leader in the discovery and development of next generation targeted protein degradation (TPD) medicines, addressing the challenges faced by the field to realise the full potential of this transformational modality.
The company’s proprietary Eclipsys™ Platform supports development of multiple innovative therapeutic candidates able to overcome the limitations associated with traditional TPD approaches with superior levels of efficacy and broad therapeutic applicability. The Amphista team includes pioneers and established leaders in TPD research and all phases of drug discovery and development. The company is supported by leading life science investors, including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, BioMotiv and Eli Lilly & Company.
For more information, please visit: http://www.amphista.com